Auris Health

Auris Health is a technology company.

Closed

Updated: Feb 17, 2026 ·

Recent News & Mentions

Nov 1, 2018FundingAuris Health - Series E Aug 1, 2017FundingAuris Health - Series D Sep 1, 2015FundingAuris Health - Series B Mar 1, 2014FundingAuris Health - Series A

Financial History

Auris Health has raised $684.0M across 4 funding rounds. Most recently, it raised $220.0M Series E in November 2018.

Total Raised

$684.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Nov 1, 2018	$220.0M Series E	AYANA Capital LLC, Brewer Lane Ventures, Cervin Ventures, Lightspeed Venture Partners, Lux Capital, Mithril Capital Management, Trucks Venture Capital, Union Square Ventures, Dylan Taylor
Aug 1, 2017	$280.0M Series D	AYANA Capital LLC, Brewer Lane Ventures, Cervin Ventures, Lightspeed Venture Partners, Lux Capital, Mithril Capital Management, Trucks Venture Capital, Union Square Ventures, Dylan Taylor
Sep 1, 2015	$150.0M Series B	AYANA Capital LLC, Brewer Lane Ventures, Cervin Ventures, Lightspeed Venture Partners, Lux Capital, Mithril Capital Management, Trucks Venture Capital, Union Square Ventures, Dylan Taylor
Mar 1, 2014	$34.0M Series A	AYANA Capital LLC, Brewer Lane Ventures, Cervin Ventures, Lightspeed Venture Partners, Lux Capital, Mithril Capital Management, Trucks Venture Capital, Union Square Ventures, Dylan Taylor

Financial History

Auris Health has raised $684.0M across 4 funding rounds.

Total Raised

$684.0M

Valuation

N/A

Deep Dive

High-Level Overview

Auris Health is a Silicon Valley-based medical technology company that developed robotic platforms for minimally invasive procedures, primarily focusing on enhancing physician capabilities in diagnostics and treatments like lung cancer interventions.[1][2][4][6] Its flagship product, the Monarch Platform, integrates robotics, micro-instrumentation, endoscope design, sensing, and data science to provide precise instrument control, high-definition 3D visualization, and access to hard-to-reach areas, serving physicians and patients by solving challenges in surgical precision, recovery times, and outcomes.[3][5][6] Acquired by Johnson & Johnson in 2019 for up to $3.4 billion (including milestones), the company had raised $733 million prior and grown to about 1,000 employees before integration into J&J's Medical Devices Companies.[1][2][4][6]

Origin Story

Founded in 2007 as Auris Surgical Robotics by Frederic Moll, M.D., a pioneer in surgical robotics (previously key at Intuitive Surgical, maker of the da Vinci system), the company emerged from a vision to advance beyond existing robotic surgery tools.[4][6] Moll's background in intuitive, minimally invasive tech drove the idea for platforms like Monarch, initially targeting lung cancer diagnostics via FDA-cleared bronchoscopic procedures.[6] Early traction built through integration of AI, data science, and flexible endoscopy, culminating in the 2019 acquisition by Johnson & Johnson, where Moll joined to expand robotics across orthopedics, endoluminal procedures, and J&J's Lung Cancer Initiative.[1][2][4][6]

Core Differentiators

Integrated Robotic Platform: Combines robotics, micro-instrumentation, sensing, and data science for patient-specific designs that preserve organ integrity, unlike traditional surgery.[1][2][7]
Monarch Platform Features: Offers computed guidance, continuous visualization, flexible catheter-based access to intricate areas, and enhanced precision for minimally invasive bronchoscopy and beyond.[3][5][6]
Focus on Precision and Outcomes: Enables 3D HD visualization, AI-driven data insights, and reduced complications, setting it apart in robot-assisted surgery.[3][6]
Proven Scale Pre-Acquisition: Raised $733M, reached 1,000 employees, and achieved FDA clearance, demonstrating rapid growth in healthtech robotics.[1][2][4]

Role in the Broader Tech Landscape

Auris Health rides the rise of robot-assisted surgery and data-driven healthcare, fueled by demands for precision, cost-efficiency, and minimally invasive care amid aging populations and rising chronic diseases like lung cancer.[3][6] Its timing aligned with regulatory shifts toward AI/ML in medtech and reimbursement for advanced procedures, positioning it ahead of competitors like Quantum Surgical or Activ Surgical.[3][4] Post-acquisition, it bolsters J&J's ecosystem, influencing surgical innovation from diagnostics to orthopedics via partnerships like Verb Surgical, and accelerates trends in connected, digital surgery platforms.[6]

Quick Take & Future Outlook

Integrated into J&J since 2019, Auris Health's Monarch tech is poised to expand beyond lung cancer into broader interventional robotics, driven by AI advancements and J&J's global scale.[6] Trends like AI-enhanced surgical intelligence, regulatory streamlining for robotics, and value-based care will shape its path, potentially amplifying J&J's leadership in minimally invasive procedures.[3][4][6] As robotics redefines optimal patient outcomes, Auris Health exemplifies how targeted innovation transforms medical intervention, echoing its founding mission to pioneer the next era of care.[1][2]

Sources

Frequently Asked Questions

How much funding has Auris Health raised?

Auris Health has raised $684.0M in total across 4 funding rounds.

Who are Auris Health's investors?

Auris Health's investors include AYANA Capital LLC, Brewer Lane Ventures, Cervin Ventures, Lightspeed Venture Partners, Lux Capital, Mithril Capital Management, Trucks Venture Capital, Union Square Ventures, Dylan Taylor.